Viking Therapeutics, Inc. (NASDAQ:VKTX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2019 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company was held on May 23, 2019. At the Annual Meeting, the Company’s stockholders elected the Class I director nominees of the Company and ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2019 (together, the “Proposals”). Each Proposal is described in detail in the Company’s definitive proxy statement for the Annual Meeting that was filed with the U.S. Securities and Exchange Commission on April 5, 2019. As of April 1, 2019, the record date for the Annual Meeting, 72,027,657 shares of the Company’s common stock were issued and outstanding. The final votes on the Proposals presented at the Annual Meeting are as follows:
Proposal 1. Election of Class I Director Nominees
Matthew W. Foehr and Charles A. Rowland, Jr. were each elected as Class I directors at the Annual Meeting to serve until the Company’s 2022 Annual Meeting of Stockholders, and until his respective successor is duly elected and qualified. The final voting results were as follows:
Proposal 2. Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2019. The final voting results were as follows:
About Viking Therapeutics, Inc. (NASDAQ:VKTX)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
